A safety review and meta-analyses of bevacizumab and ranibizumab: Off-label versus goldstandard

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Schmucker, Christine ^a   Ehlken, Christoph ^a   Agostini, Hansjuergen T ^a   Antes, Gerd ^a   Ruecker, Gerta ^a   Lelgemann, Monika ^b   Loke, Yoon K ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Medical Advisory Service of the German Health Insurance Funds   (Germany)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; TRIAMCINOLONE;

ARTERIAL THROMBOEMBOLISM; BLEEDING; BLOOD VESSEL OCCLUSION; CEREBROVASCULAR ACCIDENT; CHOROID DETACHMENT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG SAFETY; DUODENAL ULCER BLEEDING; EMBOLISM; ENDOPHTHALMITIS; EYE DISEASE; GASTRIC ULCER BLEEDING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GOLD STANDARD; HEART INFARCTION; HUMAN; INFECTION; LENS DISEASE; META ANALYSIS; NAUSEA; OFF LABEL DRUG USE; PHOTODYNAMIC THERAPY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; REVIEW; STROKE; SUBDURAL HEMATOMA; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; UVEITIS; VITREOUS HEMORRHAGE; VOMITING;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIAS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; EYE; HUMANS; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84864569800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042701     Document Type: Review

References (43)

1. Bressler NM, (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291: 1900-1901.
2. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, et al. (1977) The Framingham Eye Study: I. Outline and major prevalence findings. Am J Epidemiol 106: 17-32.
3. Ferris FL, Fine SL, Hyman L, (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102: 1640-1642.
4. Steinbrook R, (2006) The price of sight- ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 355: 1409-1412.
5. US Food and Drug Administration (FDA) MedWatch (2005) Safety: Avastin (bevacizumab). Available: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150721.htm via the Internet. Accessed 20 February 2012.
6. Hapani S, Sher A, Chu D, Wu S, (2010) Increased risk of serious haemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79: 27-38.
7. Ranpura V, Hapani S, Wu S, (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305: 487-494.
8. Michels S, (2006) Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol 90: 1333-1334.
9. Rosenfeld PJ, Moshfeghi AA, Puliafito CA, (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36: 331-335.
10. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, et al. (2007) Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 125: 1357-1361.
11. Lazic R, Gabric N, (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114: 1179-1185.
12. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, et al. (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe's Arch Clin Exp Ophthalmol 246: 81-87.
13. Chen CY, Wong TY, Heriot WJ, (2007) Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 143: 510-512.
14. CATT Research Group (2011) Martin DF, Maguire MG, Ying GS, Grunwald JE, et al. (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897-1908.
15. Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, et al. (2011) Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 95: 308-317.
16. Centre for Reviews and Dissemination (2008) Systematic reviews of adverse effects. In: Systematic Reviews - CRD's guidance for undertaking reviews in health care. York: University of York. 177-198.
17. R Development Core Team (2008) R: A language and environment for statistical computing. Available: http://www.R-project.org via the Internet. Accessed 16 Jan 2012.
18. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A, (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26: 53-77.
19. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, et al. (2011) Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 59: 191-196.
20. Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, et al. (2010) Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye 24: 1708-1715.
21. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, et al. (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116: 57-69.
22. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
23. Abraham P, Yue H, Wilson L, (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150: 315-324.
24. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, et al. (2009) A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116: 1731-1739.
25. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, et al. (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118: 831-839.
26. Sacu S, Michels S, Prager F, Weigert G, Dunavoelgyi R, et al. (2009) Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye 23: 2223-2237.
27. Costagliola C, Romano MR, Rinaldi M, dell'Omo R, Chiosi F, et al. (2010) Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 94: 180-184.
28. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, et al. (2010) Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 340: c2459.
29. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, et al. (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444.
30. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, et al. (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144: 850-857.
31. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, et al. (2009) Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 127: 13-21.
32. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, et al. (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114: 246-252.
33. Kaiser PK, Blodi BA, Shapiro H, Acharya NR, (2007) MARINA Study Group (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114: 1868-1875.
34. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, et al. (2007) Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 125: 1460-1469.
35. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, et al. (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degnereation: PIER study year 1. Am J Ophthalmol 145: 239-248.
36. Weigert G, Michels S, Sacu S, Varga A, Prager F, et al. (2008) Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 92: 356-360.
37. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, et al. (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114: 2179-2182.
38. Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, et al. (2007) Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27: 1260-1266.
39. Chou R, Aronson N, Atkins D, Ismaila AS, Santaguida P, et al. (2010) Assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. J Clin Epidemiol 63: 502-512.
40. Food and Drug Administration (2006) Highlights of prescribing information, Lucentis (Genentech). Available: www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf via the Internet. Accessed 17 Feb 2012.
41. Curtis LH, Hammill BG, Schulman KA, Cousins SW, (2010) Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration. Arch Ophthalmol 128: 1273-1279.
42. van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, et al. (2011) A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 31: 1449-1469.
43. The Royal College of Ophthalmologists Statement (2011) Bevacizumab (Avastin) use in medical ophthalmology. Available: http://www.rcophth.ac.uk/news.asp?section=24§ionTitle=News&itemid=647 via the Internet. Accessed 02 April 2012.